RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q4 FY20 results · Jan–Mar 2020
RPG Life Sciences reported revenue from operations of ₹88.67 crore (up 28.9% from Q4 FY19) and net profit of ₹2.98 crore (up 93.5% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a standalone basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 88.67 | 68.80 | +28.9% | 94.37 | −6.0% |
| Other income | 0.38 | 0.42 | −9.5% | 0.04 | +850.0% |
| Total income | 89.05 | 69.22 | +28.6% | 94.41 | −5.7% |
| Profit before tax | 3.14 | 2.12 | +48.1% | 10.41 | −69.8% |
| Net profit for the period | 2.98 | 1.54 | +93.5% | 7.91 | −62.3% |
| EPS, basic (₹) | 1.80 | 0.93 | +93.5% | 4.78 | −62.3% |
| Net margin (%) | 3.4 | 2.2 | 8.4 |
Standalone
- Filed with BSE
- 06 Jun 2020, 14:56 IST
- Board meeting
- 05 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE